Lopinavir News and Research

RSS

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Researchers recently demonstrated that chemical agents capable of reducing disulfide (S-S) bonds can be potentially used as antiviral drugs against SARS-CoV-2, the causative pathogen of COVID-19.

6 Jan 2021

Researchers identify natural products with potential to disrupt viral spread

Researchers at Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego have broken down the genomic and life history traits of three classes of viruses that have caused endemic and global pandemics in the past and identify natural products - compounds produced in nature - with the potential to disrupt their spread.

5 Jan 2021

Azithromycin trial fails to provide evidence of benefit in COVID-19

Early on in the COVID-19 pandemic, azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, SARS-CoV-2.

16 Dec 2020

Copper gluconate supplementation could reduce SARS-CoV-2 infection in vitro

The second wave of COVID-19 has affected many countries, costing thousands of lives and dealing further heavy blows to already reeling economies.

16 Dec 2020

Favipiravir does not attenuate the progression of COVID-19

Scientists have conducted an observational study to evaluate the efficacy of an anti-influenza medicine favipiravir in treating hospitalized COVID-19 patients.

11 Dec 2020

Researchers use AI platform to identify best combination of available therapies against COVID-19.

A team of researchers from the National University of Singapore (NUS) has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

11 Dec 2020

Using AI to find optimal combination of available therapies against SARS-CoV-2

A team of researchers from the National University of Singapore has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

10 Dec 2020

New insight into role of autophagy in controlling SARS-CoV-2 infection

A team of researchers at the University of Manitoba in Canada said that nanoparticle targeting of autophagy at the sites could be a potent tool to effectively overcome COVID-19 while preventing the common adverse effects of the drug.

2 Dec 2020

Chinese woman still sheds SARS-CoV-2 over four months post-infection

A new study by Chinese scientists explore an unusual case of extended viral shedding in a 68-year-old woman up to four months post-infection.

1 Dec 2020

Nucleic acid-hydrolyzing scFv 3D8 exhibits potent antiviral effects on SARS-CoV-2

3D8, a 27-kDa recombinant antibody fragment, was found in autoimmune-prone Murphy Roths Large mice. The single-chain variable fragment (scFv) has the nucleic acid hydrolyzing activity and is shown to degrade DNA or mRNA of viruses in infected cells.

30 Nov 2020

Resveratrol shows potential as SARS-CoV-2 antiviral, study finds

A recent study reveals that resveratrol, a phenolic compound produced by spermatophytes, can inhibit the viral replication SARS-CoV-2.

27 Nov 2020

Largest clinical trial launched to treat mild-to-moderate COVID-19 patients in Africa

Thirteen African countries and an international network of research institutions have joined forces to launch the largest COVID-19 clinical trial in mild-to-moderate outpatients in Africa.

24 Nov 2020

Pomegranate peel extract shows potential as inhibitor of SARS-CoV-2 virus

Researchers led by first author Relja Suručić from the Department of Pharmacognosy, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina, have studied the use of pomegranate peel extracts in preventing infections with SARS-CoV-2.

22 Nov 2020

Reducing the airborne transmission risk for SARS-CoV-2

Rapid Reviews: COVID-19 (RR:C19), an open-access overlay journal published by the MIT Press that accelerates peer review of COVID-19-related research preprints, is currently soliciting reviews of the following COVID-19 preprints.

6 Nov 2020

WHO study finds Remdesivir and other repurposed drugs ineffective in COVID-19

A large-scale randomized trial has recently been conducted by the World Health Organization (WHO) to evaluate the efficacy of four repurposed antiviral medicines, including Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon, currently used to treat hospitalized coronavirus disease 2019 (COVID-19) patients.

18 Oct 2020

Control trial proves effectiveness of repurposed drugs for COVID-19 treatment

In just six months, the world's largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19.

16 Oct 2020

Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro

Among them is the combination of lopinavir and ritonavir, which have been in use in an attempt to reduce the severity of the disease. However, a new South Korean study published on the preprint server bioRxiv in September 2020 shows that this combination is ineffective against the virus.

20 Sep 2020

Identifying, preventing and treating drug-induced arrhythmias

Health care professionals should become more familiar with medications that cause irregular heart rhythms called arrhythmias, according to "Drug- Induced Arrhythmias," a new scientific statement from the American Heart Association, published today in the Association's flagship journal Circulation.

15 Sep 2020

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Now, a new study published on the preprint server bioRxiv in August 2020 reports on the identification of 14 compounds that can inhibit the key viral enzyme called the Main Protease (MPro) at micromolar concentrations.

1 Sep 2020

Inhaled steroid ciclesonide suppresses SARS-CoV-2 replication in vitro

A new paper by researchers at Japan’s National Institute of Infectious Diseases and published on the preprint server bioRxiv in August 2020 reports the in vitro suppression of coronavirus (CoV) replication by an inhaled corticosteroid (ICS) ciclesonide.

26 Aug 2020